ReviewBlood cancer journal2015
Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Review in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 4 syntheses or guidelines pooled it, 278 citations in OpenAlex.
- Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2020Pooled it
- Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis.Scientific reports · 2017Pooled it
- Pooled it
- Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study.Journal of cancer research and clinical oncology · 2021Trial
- Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.Proteomics. Clinical applications · 2019Trial
- Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia.PloS one · 2019Trial
- Article
- Differentiation Treatment Applied to Lung Cancer Model Reduces Pathogenic Traits in Vitro.Advanced biology · 2026Article
- A rare case of variant acute promyelocytic leukemia withLeukemia research reports · 2026Article
- A Rare t(3;15;17) in a Patient with Acute Promyelocytic Leukemia: Case Report and Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Article
- Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis.Molecular cancer therapeutics · 2025Article
- Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: molecular basis and new targets.Frontiers in oncology · 2025Review
- Identifying Differential Methylation in Cancer Epigenetics via a Bayesian Functional Regression Model.Biomolecules · 2024Article
- Natural products as potential drug treatments for acute promyelocytic leukemia.Chinese medicine · 2024Review
- The Role of Transglutaminase 2 in Cancer: An Update.International journal of molecular sciences · 2024Review
- miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.Annals of hematology · 2023Article
- Review
- Reprogramming of Acute Myeloid Leukemia Patients Cells: Harboring Cancer Mutations Requires Targeting of AML Hierarchy.Stem cells translational medicine · 2023Article
- Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Historically, acute promyelocytic leukemia (APL) was considered to be one of the most fatal forms of acute leukemia with poor outcomes before the introduction of the vitamin A derivative all-trans retinoic acid (ATRA). With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼80%, even higher among low-risk patients. Furthermore, with ATRA-ATO combinations, chemotherapy may safely be omitted in low-risk patients. The disease is now considered to be the most curable subtype of acute myeloid leukemia (AML) in adults. Nevertheless, APL remains associated with a significant incidence of early death related to the characteristic bleeding diathesis. Early death, rather than resistant disease so common in all other subtypes of AML, has emerged as the major cause of treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.